3 Biotechs Looking Good This Earnings Season

The biotech sector has seen a lot of changes over the last year. And when we talk of biotechs, we’re reminded of one of its big success stories – Gilead (GILD). Gilead’s blockbuster hepatitis C virus (HCV) drug Sovaldi was a clear winner in the HCV market ever since it was launched. The company strengthened its position further in the HCV market with the approval of Harvoni.

Gilead faced a setback in late 2014 with AbbVie's (ABBV) hepatitis C drug, Viekira Pak, gaining approval. AbbVie went on to ink a deal with Express Scripts (ESRX) and got listed in the latter’s National Preferred Formulary. Express Scripts' independent Pharmacy & Therapeutics Committee determined Viekira Pak to be at least clinically equivalent to Sovaldi and Harvoni, which were excluded from the National Preferred Formulary. Gilead’s shares were hit badly following the news.

1 2 3
View single page >> |

Disclosure: Zacks.com contains statements and ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.